Mpox: French health authorities recommend booster shot to combat risk of new outbreak
September 2, 2024
The French National Authority for Health (HAS) continues to recommend mpox vaccination for at-risk groups, despite the waning of the 2022-2023 outbreak. The target population remains unchanged, including men who have sex with men, trans individuals with multiple partners, sex workers, and those in related environments. HAS advises using the Bavarian Nordic vaccine, marketed as Imvanex in Europe. This guidance underscores the ongoing importance of preventive measures against mpox, even as public attention to the virus has decreased since the height of the previous outbreak.
The French National Authority for Health (HAS) continues to recommend mpox vaccination for at-risk groups, despite the waning of the 2022-2023 outbreak. The target population remains unchanged, including men who have sex with men, trans individuals with multiple partners, sex workers, and those in related environments. HAS advises using the Bavarian Nordic vaccine, marketed as Imvanex in Europe. This guidance underscores the ongoing importance of preventive measures against mpox, even as public attention to the virus has decreased since the height of the previous outbreak.